Skip to main content
Funded Studies

Paul Tempest, PhD

SVP and Head of Medicinal Chemistry at APRINOIA Therapeutics, Inc.

Location: Taipei, Taiwan

Dr. Paul Tempest studied chemistry at MIT (BS 1992) and UCLA (PhD 1997). He joined Amgen’s newly formed small molecule group in Thousand Oaks, Calif., where he worked on several hit-to-lead projects in CNS, CV and oncology and developed novel chemistry for heterocyclic libraries, as well as property- and target-based focused libraries. In 2001 Dr. Tempest transferred to Amgen-Cambridge focusing on kinases in the lead ID space. He then joined the newly created Merck Boston research site in 2004, leading a parallel medicinal chemistry group and contributing to all medicinal chemistry projects on site including oncology and CNS areas in both hit-to-lead and lead ID space. In 2009, he left Boston for Shanghai, China with ChemPartner-Shanghai. In Shanghai, he led >20 integrated medicinal chemistry projects for clients from virtual companies to big pharma, including CNS, oncology, metabolic disease and ADC projects. In 2015, Dr. Tempest joined APRINOIA as head of medicinal chemistry. He persists in trying to study Chinese and now resides in Taiwan.

Associated Grants

  • Alpha-Synuclein PET Imaging Tracer Development


We use cookies to ensure that you get the best experience. By continuing to use this website, you indicate that you have read our Terms of Service and Privacy Policy.